Fiche publication
Date publication
janvier 2026
Journal
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric
,
Pr GERMAIN Adeline
Tous les auteurs :
Cazelles A, Denost Q, Fernandez B, Rivoire M, Meillat H, Rouanet P, Karoui M, Germain A, Maggiori L, Valverde A, Peru N, Cotte E, Buscail E, Lefevre JH, Trilling B, Faucheron JL, Sage PY, Beyer-Berjot L, Benoist S, Alves A, Sabbagh C, Tuech JJ, Coget J, Marchal F, Meurette G, Mège D, Djelil D, Manfredelli S, Venara A, Ouaissi M, Manceau G,
Lien Pubmed
Résumé
Neoadjuvant treatment for rectal cancer has evolved markedly with the growing adoption of total neoadjuvant therapy (TNT), organ-preservation strategies and selective omission of radiotherapy. Recent trials support risk-based personalization, but its application in real-world settings remains poorly documented. The aim was to describe current neoadjuvant treatment practices for mid-low rectal cancer in French expert centres and identify tumour- and patient-related factors influencing decisions.
Mots clés
locoregional tumour extension, neoadjuvant treatment, observational study, patient age, rectal cancer, total neoadjuvant treatment
Référence
Colorectal Dis. 2026 01;28(1):e70358
